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Objectives: The objective of this cross-sectional, observational study was to investigate 
performance of activities of daily living in patients with myotonic dystrophy type 1 (DM1). 
Materials & Methods: Adults with genetically confirmed late- or adult-onset DM1 were 
recruited from Newcastle University (Newcastle upon Tyne, UK) and University College 
London Hospitals NHS Foundation Trust (London, UK) as part of the PhenoDM1 study. 
Data on activities of daily living was recorded through the DM1-ActivC (scale scores range 
between 0 and 100, where a higher/lower score indicates a higher/lower ability). 
Results: Our sample comprised 192 patients with DM1 (mean age: 46 years; 51% female). 
Patients reported most difficulties with running, carrying and putting down heavy objects, 
and standing on one leg, and least difficulties with eating soup, washing upper body, and 
taking a shower. Irrespective of the disease duration (mean: 20 years), most patients were 
able to perform examined basic and instrumental activities of daily living, with the exception 
of functional mobility/transfer tasks (e.g., walking uphill and running). The mean DM1-
ActivC total score was estimated at 71 (95% CI: 68–74). Estimated progenitor cytosine-
thymine-guanine repeat length and age explained 27% of the variance in DM1-ActivC total 
scores (p < 0.001). 
Conclusions: We show that DM1 impairs performance of activities of daily living, in 
particular those requiring a high degree of muscle strength, stability, and coordination. Yet, 
across the lifetime of the disease, the majority of patients will still be able to independently 
perform most basic and instrumental activities of daily living.  
 






Myotonic dystrophy type 1 (DM1) is a rare, disabling neuromuscular disorder of varying 
severity caused by the expansion of the cytosine-thymine-guanine (CTG) triplet repeat in the 
DMPK gene.1 Longer CTG triplets expansion has been shown to be related to greater disease 
severity and earlier age at onset. DM1 is the most common muscular dystrophy with an 
estimated prevalence of 8 per 100,000.2 Typical manifestations of DM1 include muscle 
weakness, myotonia, and fatigue, but symptoms are heterogeneous and may also involve 
other organs and systems, such as the heart and eyes, and the endocrine, gastrointestinal, and 
central nervous system.  
 
In recent decades, the increased understanding of the underlying molecular pathology of 
DM1 has enabled the design of new targeted treatments, including antisense oligonucleotides, 
GSK3 inhibitors, and other pharmacological and genetic treatments.3 This acceleration in 
therapy development has resulted in a pressing need to map out the natural history of the 
disease to inform the design of clinical trial programs, including the selection of appropriate 
clinical endpoints and tools that are fit for purpose to measure drug benefits.4,5  
 
The DM1 activity and participation scale for clinical use (DM1-ActivC) is a rating-scale 
designed to measure self-reported performance of activities of daily living (e.g., brushing 
teeth, preparing meals, and walking up a flight of stairs) in patients with DM1. The tool was 
initially developed in 2010,6 but re-constructed in 2015,7 and the current version encompasses 
a total of 25 items, each described in three levels. The DM1-ActivC has been tested using 
modern psychometric analysis (i.e., Rasch analysis8) and has been shown to adhere to the 




Since its development, the DM1-ActivC has been employed as part of a few studies,11,12 and 
the instrument was also included in a recently completed multi-national trial in DM1 (i.e., the 
OPTIMISTIC trial).13 However, to date, no study has reported results from the DM1-ActivC 
beyond summary point estimates of mean instrument scores. Accordingly, the objective of 
this study was to investigate the impact of DM1 on activities of daily living as recorded using 
the DM1-ActivC in patients with DM1 from the UK. A specific aim was to examine if the 
disease burden varies by sex, disease duration, and several clinical measures and biomarkers 




Materials & Methods 
 
Study design and patient sample 
This study was based on a sample of patients with DM1 recruited from two sites in the UK 
(Newcastle University, Newcastle upon Tyne, and University College London Hospitals NHS 
Foundation Trust, London) as part of the Myotonic Dystrophy Type 1 Deep Phenotyping to 
Improve Delivery of Personalized Medicine and Assist in the Planning, Design and 
Recruitment of Clinical Trials (PhenoDM1) study (ClinicalTrials.gov identifier: 
NCT02831504). To be eligible to participate, all patients were required to meet the following 
inclusion criteria: (i) ≥18 years of age, (ii) genetically confirmed diagnosis of late- or adult-
onset DM1, and (iii) ability to perform the 10 meters walking test at selected pace without 
any assistance (walking devices allowed). All participants provided informed consent to 
participate in the study and ethical approval was granted by the Newcastle and North 
Tyneside Ethics Committee (reference: NE/15/0178). 
 
Study procedures and outcome measures 
Eligible patients were asked to complete the DM1-ActivC as part of the study visits. We also 
recorded data from patients concerning their basic demographic and clinical characteristics as 
shown in Table 1. As outcome measure of functional ability, the 6MWT was included for 
comparison. The test was performed in a 25-meter long corridor in Newcastle and 20-meter 
long corridor in London with input every minute per currently agreed procedures.4  
 
Genetic analysis 
Recent studies have shown that the length of the repeat expansion at birth as expressed by the 
progenitor allele is the most relevant predictor of disease onset and severity later in life, while 
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disease progression is closely related to the rate of somatic expansion over time within 
different tissues (approximated as the difference between modal length at the time of DNA 
sampling and the progenitor allele, where the modal allele length is the most common repeat 
length in that tissue at time of sampling). For our analysis, we included both  
CTG repeat counts from blood DNA (i.e., the estimated progenitor and modal allele length) 
to allow comparison of data. The genetic analysis was completed using the CTG repeat-
flanking primers DM-C and DM-DR.15,16 Replicate reactions were separated by gel 
electrophoresis, Southern blotted and hybridised using a 32P-labelled 56 x CTG repeat probe. 
Bands were detected by autoradiography and sized by comparison against the DNA 
molecular weight marker, using CLIQS software (TotalLab UK Ltd.). The bottom edge of the 
expanded allele bands was used to determine the ePAL16 The densest part of the expanded 
allele bands was used to estimate the modal allele length at the time of DNA sampling (i.e. 
CTG modal alleles).  
 
Statistical analysis 
We calculated the distribution of replies across all items and levels within the DM1-ActivC 
and the corresponding mean item scores, ranging from 0 (“Not possible to perform”) to 2 
(“Possible, without any difficulty”), as well as the mean transformed total instrument score 
(ranging between 0 and 100, where a higher/lower score indicates a higher/lower ability to 
perform activities of daily living). We related the total score to two previously derived7 
threshold values (amended for the transformed scale): ≤30 (indicating severe limitations in 
activities of daily living), and >70 (indicating relativity few limitations). We summarized the 
three most difficult activities (i.e., the items with the lowest mean scores), as well as the three 
easies activities (i.e., the items with the highest mean scores), in the pooled sample and by 
patient age (i.e., <30 years vs. ≥30 years, as limitations in activities of daily living, as well as 
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the DM1-ActivC scoring algorithm, have been shown to be different for these strata7]), 
respectively. We also calculated the proportion of patients able to perform (with or without 
help) included activities of daily living (i.e., “Possible, without any difficulty” or “Possible, 
but with some difficulty” vs. “Not possible to perform”). Moreover, to examine the predictive 
properties of individual item levels with respect to the mean DM1-ActivC total score, we 
derived and presented the mean DM1-ActivC total score by item levels. We derived the 
proportion of patients able to perform (with or without help) included activities of daily living 
by four categories of disease duration (<10 years, 10–20 years, 20–30 years, and ≥30 years, 
measured from onset) and compared total DM1-ActivC scores by sex using Welch’s t-test. 
We also estimated Pearson’s correlation coefficients to investigate the crude relationship 
between DM1-ActivC total scores and disease duration, CTG repeat length, the Muscular 
Impairment Rating Scale (MIRS) score, and 6MWT result, respectively, and also derived 
linear trends using the ordinary least squares method. Finally, to further explore the 
relationship between estimated progenitor CTG repeat length and performance of activities of 
daily living, we fitted an ordinary least squares regression model to the study data, with the 
mean DM1-ActivC total score as the dependent variable and estimated progenitor CTG repeat 
length and age, as well as an interaction variable between estimated progenitor CTG repeat 
length and age, as independent variables (with estimated progenitor CTG repeat length 







A total of n = 192 adult patients with DM1 met the study inclusion criteria and completed the 
DM1-ActivC in accordance with the instructions. Summary descriptive statistics of the 
sample are presented in Table 1. Mean estimated progenitor and modal allele length, 
available for n = 104 and n = 102 patients, respectively, was 245 CTG repeats (SD: 178, 
range: 54–916) and 479 CTG repeats (SD: 346, range: 57–1,441). 
 
The distribution of replies to the DM1-ActivC are presented in Figure 1, sorted by mean item 
score (ranging between 0 to 2). Patients were able, although with some difficulty, to perform 
most activities of daily living captured by the scale. The three most difficult activities (i.e., 
the items with the lowest mean scores) were “Run” (mean item score: 1.0), “Carry and put 
down heavy object (10 kg)” (1.1), and “Stand on one leg” (1.2). The three easiest activities 
were “Eat soup” (1.9), followed by “Wash your upper body” (1.9) and “Take a shower” (1.8). 
In patients <30 years of age (n = 19), the three most difficult activities were “Carry and put 
down heavy object (10 kg)” (0.8), “Vacuum clean” (1.3), and “Stand up from squatting 
position” (1.3), and the three easiest “Eat soup” (1.9) and “Dress your lower body” (1.8), and 
“Take a shower” (1.8). Results for patients ≥30 years of age (n = 173) were identical to 
estimates for the total sample. 
  
The mean DM1-ActivC total score was estimated at 71 (SD: 21, range: 28–100, 95% CI: 68–
74). Approximately 1% (2 of 192) scored ≤30 (indicating severe limitations in activities of 
daily living), and 47% (91 of 192) >70 (indicating relativity few limitations). There were no 
significant differences between women and men in estimated mean DM1-ActivC total scores 




We found disease duration to be significantly associated with the mean DM1-ActivC total 
score (ρ = -0.29, p < 0.001). Specifically, the mean score in patients with a duration of <10 
years was estimated at 79 (SD: 22, 95% CI: 71–86, n = 40), between 10 and 20 years at 75 
(SD: 19, 95% CI: 70–80, n = 57), between 20 and 30 years at 67 (SD: 21, 95% CI: 60–73, n = 
46), and ≥30 years at 62 (SD: 20, 95% CI: 56–69, n = 39). Figure 2 presents the proportion of 
patients able (with or without difficulties) to perform the activities of daily living exhibiting 
the largest change across categories of disease duration (i.e., <10 years vs. ≥30 years). 
Results for additional tasks covered by the scale, exhibiting a mean change across categories 
of disease duration of <2.10 percentage units, are presented as supplemental material online.  
 
Results from our correlation analysis showed that DM1-ActivC total score was significantly 
associated with estimated progenitor CTG repeat length (i.e., the length of the repeat 
expansion at birth) (ρ = -0.36, p < 0.001), modal allele CTG repeat length (i.e., the length of 
the repeat expansion at DNA sampling) (ρ = -0.42, p < 0.001), MIRS score (ρ = -0.61, p < 
0.001), and 6MWT result (ρ = 0.66, p < 0.001). Scatter plots for these variable-pairs, as well 
as crude linear trends, are presented in Figure 3. Outcomes from our regression analysis also 
showed that the estimated progenitor CTG repeat length and age were able to explain 27% of 
the variance in DM1-ActivC total scores (R2 = 0.27, p < 0.001). In total, five patients had 
CTG repeat interruptions, and their mean DM1-ActivC total score was 62 (SD: 15, range 48–









The objective of this study was to investigate the impact of DM1 on activities of daily living 
as recorded using the DM1-ActivC, and investigate the association between impairment and 
disease duration, genotype, and phenotype. Taken together, our results show that most men 
and women with DM1 experience some limitations in performance of many common 
household and leisure tasks (Figure 1). However, our examination of specific activities 
revealed that only a few were impaired in a progressive pattern from onset. In particular, 
irrespective of the duration of the disease, the vast majority of patients in our sample were 
still able to perform examined basic activities of daily living (e.g., personal hygiene and 
grooming, showering, and eating), with the exception of functional mobility/transfers (e.g., 
walking uphill and running). Most patients (>80% per task) were also able to perform 
included instrumental activities of daily living (e.g., cleaning and shopping), as well as 
visiting family or friends. In general, across the lifetime of the disease, the activities affected 
the most were those recognized with major demands of muscle strength, stability, and 
coordination, for example standing on one leg, carrying and putting down heavy objects, and 
running. Yet, even after 30 years of onset of symptoms, almost half of our cohort were still 
able, although with some problems, to perform the most difficult tasks studied (Figure 2). 
 
We found that the easiest tasks included in the DM1-ActivC were “Eat soup”, “Wash your 
upper body”, and “Take a shower” (“Wash your upper body” replaced by “Dress your lower 
body” in patients <30 years of age). These findings are comparable to the ranking of 
instrument items based on the psychometric Rasch analysis of the tool,7 which identified “Eat 
soup”, “Visit family or friends”, and “Care for your hair and body” as the easiest tasks 
(“Wash your upper body” and “Take a shower” were ranked the fifth and sixth easiest, 
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respectively). The ordering of items in terms of difficulty was also similar to the Rasch 
analysis output, with some exceptions. Specifically, in patients <30 years of age, the most 
difficult items were “Carry and put down heavy object (10 kg)”, “Vacuum clean”, and “Stand 
up from squatting position” in our study, and “Run”, “Carry and put down heavy object (10 
kg)”, and “Walk 3 flights of stairs” in the Rasch analysis. Corresponding results for those ≥30 
years of age were “Run”, “Carry and put down heavy object (10 kg)”, and “Stand on one 
leg”, and “Carry and put down heavy object (10 kg)”, “Walk 3 flights of stairs”, and “Walk 
uphill”, respectively. It is not possible, based on the data at hand, to further analyze potential 
reasons for these inconsistencies. However, when comparing our results with the Rasch 
study, it is important to keep in mind that we only included patients that were able to walk a 
minimum of 10 meters without the assistance of somebody else and who had the capacity to 
understand the study information and consent to participating in the study, which means that 
the most functionally and cognitively impaired patients were not included. Future research 
should aim to include also patients with lower levels of ability, and also explore changes over 
time, to further broaden the understanding of the impact of DM1 across the evolution of the 
disease. In particular, to help inform the design of trials with endpoints defined in terms of 
the DM1-ActivC, it would be of interest to examine variability in annual changes in the total 
score across categories of baseline ability (which may serve as a meaningful criterion for trial 
inclusion), as well as clinical and genetic measures. Further translation and validation of the 
DM1-ActivC to other cultural settings should also constitute a prioritized topic for future 
studies of the scale.  
 
The CTG repeat length in the PhenoDM1 patient cohort was found to correlate with DM1-
Activc total score, MIRS and the 6MWT. The estimated inherited, or progenitor, allele length 
was previously shown to be the single largest factor accounting for variation in age at disease 
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onset, with a further contribution from somatic instability (Morales, 2012). This suggests that 
repeat length is the most important determinant of the underlying biology of the disease. 
Since DM1-Activc total score, MIRS and the 6MWT correlate with estimated CTG repeat 
length, they may also capture some aspect of disease mechanism, which suggests they could 
represent useful outcome measures for clinical trials. These three measures were also found 
to correlate with estimated progenitor allele length in the baseline data collected from the 
OPTIMISTIC patient cohort (Cumming, 2019). 
 
Five of the PhenoDM1 cohort tested were found to have AciI-sensitive variant repeat 
interruptions. These have previously been shown to result in reduced somatic instability and 
delayed disease onset (Overend, 2019, Cumming 2019). Further, in several different 
phenotypic measures, individuals with variant repeats scored better (Overend, 2019, 
Cumming, 2019). This does not appear to be the case in the current study for DM1-Activc 
total score, however the number of identified individuals bearing variant repeats is relatively 
small. In any future natural history studies or clinical trials, it will be very important to 
identify any individuals with variant repeat interruptions, as they can profoundly alter 
symptoms and, potentially, response to therapies.        
 
Comparing our results with previous research based on the DM1-ActivC, selected outcomes 
of the scale have been described as part of three recently published studies. DiPaolo et al.11 
reported correlation coefficients between the scale for the assessment and rating of ataxia 
(SARA) and DM1-ActivC total scores in a subset of 54 patients (mean age: 48 years; 39% 
female) from the same sample population as our study. Similar to our findings with respect to 
the 6MWT, the authors identified a significant relationship between the two measures (ρ = -
0.75, p < 0.001). Moreover, in a study investigating body composition in DM1, Sedehizadeh 
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et al.12 estimated the mean DM1-ActivC total score at 28 (using the first version of the scale6) 
in a sample of 38 patients with DM1 from the UK (mean age: 42 years; 47% female). 
However, due to differences in instrument versions, this point estimate is not easily 
comparable to our data. Finally, the DM1-ActivC was the primary outcome measure in the 
OPTIMISTIC clinical trial,13 but no scale data were published except for differences in total 
scores between examined interventions. 
 
A number of studies have investigated the impact on DM1 on activities of daily living 
quantified using measures other than the DM1-ActivC. For example, Kierkegaard et al.17 
studied functioning and disability in a sample of 70 patients with DM1 (mean age: 45 years; 
59% female) using the extended Katz Index of Independence in Activities of Daily Living 
and the Frenchay activities index (among other measures). In line with our results, although 
not directly comparable due to different scales and definitions employed, the authors found 
participation restrictions in social and lifestyle activities in 52% of patients and dependence 
in personal and instrumental activities of daily living in 16% and 39%, respectively. 
Impairment in performance of activities of daily living in DM1 was also reported by Van 
Heugten et al.18 based on data recorded via the Utrecht Scale for Evaluation of 
Rehabilitation-Participation in a sample of 66 Dutch patients (mean age: 47 years; 46% 
female). In particular, similarly to our data, the authors found most restrictions concerning 
sports/leisure activities and activities outside the home environment, but also housekeeping. 
Comparable findings were described by Gagnon et al.,19 who found most impact in the 
Recreation, Mobility, and Housing domains (in addition to Employment) based on the 
Assessment of Life Habits (LIFE-H) tool in a sample of 158 Canadian adults with DM1 




In our sample, the crude mean DM1-ActivC total score was similar for women and men with 
the disease. In contrast, previous research has indicated that men are subject to greater 
morbidity, including more severe muscular disability and cognitive impairment, and higher 
mortality. In our previous research, we found that that a larger proportion of women with 
DM1 experienced considerable fatigue and depressive feelings; however, there was no 
difference between sexes with respect to the overall disease burden. Based on our data, it not 
possible to further analyze potential sources for these inconsistent findings, but future studies 
of these topics are warranted. 
 
A limitation of our study concerns the precision and external validity of our results due to the 
relatively small sample size (although it should be noted that our sample was fairly large in 
the context of outcomes research in DM120). It is also worth noting that we interpreted 
limitations in activities of daily living in relation to full ability, despite the fact that a non-
trivial proportion of members of the general population also experience some impairment. 
Additionally, the DM1-ActivC data may be subject to bias due to, for example, incorrect 
reporting. However, the inclusion criteria of this study filtered patients with congenital 
phenotype and/or those with significant cognition impairments, whom would be expected to 
increase the risk of these type of errors. Finally, it should be noted that it is always 
theoretically possible that an association between two variables detected in observational 
research is spurious in the sense that the association does not represent a causal effect of one 
of the variables on the other.21 Consequently, we were unable to infer causality when 
interpreting results from our statistical analyses. 
 
In conclusion, we show that DM1 impairs performance of activities of daily living, in 
particular those requiring a high degree of muscle strength, stability, and coordination. Yet, 
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across the lifetime of the disease, the majority of patients will still be able to perform most 
basic and instrumental activities of daily living. 
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Table 1: Demographic and clinical characteristics of the patient sample 
Age, mean (SD) years 46 (13) 
Sex, female 97 (51%) 
Age at first symptoms, mean (SD) years* 26 (16) 
Disease duration, mean (SD) years** 20 (12) 
Part-time wheelchair dependency 25 (13%) 
Six-minute walk test result, mean (SD) meters*** 418 (154) 
Muscular Impairment Rating Scale (MIRS) score  
  I 21 (11%) 
  II 55 (29%) 
  III 41 (21%) 
  IV 57 (30%) 
  V 18 (9%) 
Education, mean (SD) years completed**** 15 (3) 
Current occupation  
  Employed 79 (41%) 
  Retired 26 (14%) 
  Long-term sick leave 45 (23%) 
  Unemployed/other 42 (22%) 
Note: Data presented as n (%), if not specified otherwise. Total sample: n = 192, excluding missing values for n 







Figure 1: Distribution of replies to the DM1-ActivC items 
 
Figure 2: Proportion of patients able to perform selected activities of daily living, by disease duration 
 
Figure 3: Association between 6MWT result, MIRS score, CTG repeat size, and DM1-ActivC total score 
 
 
